Popular Stories

Diabetes Tag

  • All
  • Biotechnology
  • Cannabis
  • Education
  • Investing Ideas
  • Macro
  • Miscellaneous
  • Sectors
  • Startups
  • Technologies
  • Trending
  • Uncategorized
Zelira Therapeutics Aims to Disrupt the Global Medical Cannabis Market

Zelira Therapeutics (OTCQB: ZLDAF), a biopharmaceutical Company developing cannabinoid-based formulations for the treatment of a wide range of medical conditions, announced full enrollment in its Phase 1 Dose Escalation Trial in patients on long-term opioid treatment for non-cancer pain. The study intends to evaluate the...

5 Companies Bringing Innovation to the Fabry Disease Treatment Market

Fabry Disease also known as angiokeratoma corporis diffusum or alpha-galactosidase A deficiency, is an inherited disorder characterized by the buildup of globotriaosylceramide, a type of fat in the body’s cells and results in numerous disorders such as acroparesthesias (burning, tingling, or prickling sensation in extremities),...

ChromaDex Seeking to Redefine Its “Anti-Aging” Pill Persona

ChromaDex (NASDAQ: CDXC), a nutraceutical Company focussed on improving the way people age, announced the launch of a “first-of-its-kind” Phase 1 clinical study to test the safety, efficacy and potential of branded nicotinamide riboside (NR), Niagen, in improving the effects of exercise therapy in older...

Emerging Innovations in Cataract Surgery Industry

The American Academy of Ophthalmology defines cataract as the clouding of the lens through which light rays are refracted and is characterized by blurry or unclear vision, double images, sensitivity to light, difficulty in seeing well at night and seeing dull or faded color instead...

Axcella Health Granted Broad Patent Covering EMM Compositions

Axcella Health (NASDAQ: AXLA), a biotechnology Company focussed on leveraging the power of Endogenous Metabolic Modulators, announced the issuance of a third EMM-related patent covering an array of EMM compositions, including AXA1125 and AXA1957, the company’s product candidates for non-alcoholic steatohepatitis (NASH). The patent broadens...

Paratek withdraws European Marketing Authorization for Nuzyra

Paratek Pharmaceuticals (NASDAQ: PRTK), a commercial-stage biopharmaceutical Company, announced the withdrawal of its submission to the European Medicines Agency (EMA), for the grant of Marketing Authorization Application (MAA) for NUZYRA® (omadacycline). The Company was developing the candidate for two indications namely, acute bacterial skin and...

WordPress Video Lightbox Plugin